The anti-epileptic drug cenobamate was listed in Schedule V by an interim final rule published March 10 (85 Fed. Reg. 13741). Cenobamate (trade name XCOPRI) was approved by the U.S. Food and Drug Administration in November 2019 for treatment of partial-onset seizures in adult patients. Drug Enforcement Administration control is governed by expedited scheduling requirements for new ... Read More